The reaffirmation of the timeline and pathway for the Anaphylm Sublingual Film by Aquestive Therapeutics, along with the alignment with the FDA, indicates progress in the company's product development. This could potentially boost investor confidence in the company, leading to a positive impact on the stock price in the short term.